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Abstract: Nanoemulsions stabilized by traditional emulsifiers raise toxicological concerns for 
long-term treatment. The present work investigates the potential of food proteins as safer sta-
bilizers for nanoemulsions to deliver hydrophobic drugs. Nanoemulsions stabilized by food 
proteins (soybean protein isolate, whey protein isolate, β-lactoglobulin) were prepared by high-
pressure homogenization. The toxicity of the nanoemulsions was tested in Caco-2 cells using 
the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide viability assay. In vivo absorp-
tion in rats was also evaluated. Food protein-stabilized nanoemulsions, with small particle size 
and good size distribution, exhibited better stability and biocompatibility compared with nano-
emulsions stabilized by traditional emulsifiers. Moreover, β-lactoglobulin had a better emulsify-
ing capacity and biocompatibility than the other two food proteins. The pancreatic degradation 
of the proteins accelerated drug release. It is concluded that an oil/water nanoemulsion system 
with good biocompatibility can be prepared by using food proteins as emulsifiers, allowing 
better and more rapid absorption of lipophilic drugs.
Keywords: oil in water nanoemulsions, food proteins, poorly water-soluble drugs, 
  biocompatibility, in vivo absorption
Introduction
Nanoemulsions are nonequilibrium, heterogeneous systems consisting of two immis-
cible liquids in which one liquid is dispersed in another liquid as droplets with diameters 
of tens to a few hundred nanometers. Oil/water nanoemulsions have great potential 
for the delivery of poorly water-soluble drugs.1–3 The major advantages of nanoemul-
sions as drug delivery carriers include ease of fabrication, increased drug loading, 
enhanced drug solubility and bioavailability, reduced patient variability, controlled 
drug release, and protection from enzymatic degradation.1,4 To stabilize nanoemulsions, 
a large amount of surfactant (20%–30% based on the oil phase, wt%) must be used 
in the formulations, which hinders the therapeutic application of nanoemulsions due 
to toxicological concerns during long-term treatment.5–8 Another main problem with 
nanoemulsions is their thermodynamic instability, resulting in aggregation and floc-
culation; furthermore, loading a drug into a nanoemulsion system can cause droplet 
coalescence and even phase separation.9–11 Therefore, it is necessary to develop stable 
nanoemulsions using alternative safer surfactants.
Food biopolymers, especially food proteins, are widely used in formulated foods 
because they have high nutritional value and are generally recognized as safe.12,13 International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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These proteins include soybean protein isolate (SPI), whey 
protein isolate (WPI), and β-lactoglobulin (β-lg).12 SPI is a 
plant protein obtained from an abundant, inexpensive, and 
renewable resource, the soybean. It is composed almost 
exclusively of two globular protein fractions called 7S 
(β-conglycinin) and 11S (glycinin).14 11S has a hexameric 
structure with a molecular weight of 300–380 kDa and an 
isoelectric point of 4.8, whereas 7S has a structure of canava-
lin and phaseolin with a molecular weight of 18–21 kDa and 
an isoelectric point of 6.4.15 The amount of nonpolar amino 
acid residues is 62.5% (mol%) and 34.8% for 11S and 7S, 
respectively.16 WPI is derived from milk, in which the two 
most important proteins (β-lg and α-lactalbumin) account 
for about 65% of the total weight of whey protein.17,18 
α-Lactalbumin is a small, acidic, and Ca2+-binding milk 
protein with a molecular weight of 14.2 kDa and an isoelectric 
point of 4–5. Native α-lactalbumin, consisting of 123 amino 
acid residues, has two domains, ie, a large α-helical domain 
and a small β-sheet domain, which are connected by a 
  calcium binding loop.19 β-lg, which is widely used as a food 
  ingredient, is a dominant globular protein in WPI. It has a 
molecular weight of 18.4 kDa and an isoelectric point of 5.2.20 
Each monomer comprises 162 amino acids, with one free 
cysteine and two disulphide bridges.20,21 The proteins, like 
traditional surfactants, are amphiphilic. However, food 
  proteins possess good water solubility and can function as 
excellent wall materials.22–24 Thus, food proteins have better 
flexibility than surfactants and can adsorb rapidly to the 
emulsion interface, where they self-aggregate through inter-
molecular interactions and form continuous membranes 
around oil droplets.12,18 The hydrophobic residues (amino acids 
and disulfide bonds), to some extent, are buried in the protein 
interior, which is directly correlated with the surface tension 
reduction at the oil/water interface. After heat denaturation, 
nonpolar and disulfide bonds buried inside the protein will 
become exposed, which can enhance the ability of these 
proteins to adsorb to the emulsion interface.25 Most importantly, 
these food proteins have excellent biocompatibility and 
biosafety due to their ready biodegradation by proteases.13,26–30 
Therefore, we hypothesize that food proteins are safer emulsi-
fiers for nanoemulsions, which has potential for the delivery 
of poorly water-soluble drugs.
Fenofibrate (FB), a Biopharmaceutics Classification Sys-
tem Class II drug, is a highly lipophilic drug that is clinically 
used to lower lipid levels. Its therapeutic efficacy has been 
compromised for years due to virtual water insolubility in 
water and physiological fluids. It was reported that lipid-based 
formulations enhanced its oral bioavailability efficiently.31–33 
The colloidal structures formed during the digestion of 
lipids provide a series of enduring lipophilic phases within 
which lipophilic drugs might reside during gastrointestinal 
transit, preventing precipitation and enhancing absorption 
of the drugs.34
In the present work, our aim was to evaluate the ability of 
the food proteins to stabilize nanoemulsions. Considering the 
difference in structure, molecular weight, surface character-
istics, and isoelectric points, three representative   proteins, SPI, 
WPI, and β-lg, were chosen in our study. The nanoemulsions 
were characterized in terms of particle size and distribution, 
zeta potential, transmission electron microscopy (TEM) 
morphology, and resistance to centrifugation. The toxicity 
of food protein-stabilized nanoemulsions was evaluated 
in Caco-2 cells using the 3-(4,5-dimethylthiazol-2-yl)-2, 
5-diphenyltetrazoliumbromide (MTT) viability assay. 
  Specifically, a representative poorly water-soluble drug, 
FB, was loaded into oil/water nanoemulsions, and then in 
vitro release and pharmacokinetics in rats were evaluated.
Materials and methods
Materials
FB was purchased from Enhua Pharma Co., Ltd (Xuzhou, 
China). WPI was provided by Davisco Foods International Inc. 
(Le Sueur, MN, USA). SPI was obtained from Hufeng 
Chemical Industry Co., Ltd (Shanghai, China). β-lg from 
bovine milk (No. L3908, .90% purity grade) was purchased 
from Sigma Chemical Co. (St Louis, MO, USA). Cremo-
phor EL, Cremophor RH 40, Poloxamar-188, and Solutol 
HS15 were from BASF (Ludwigshafen, Germany). Polysor-
bate 80 (Tween-80) was supplied by Shenyu Pharmaceutical 
and Chemical Co., Ltd (Shanghai). Egg phosphatidylcholine 
(EPC) was purchased from Toshisun Co., Ltd (Shanghai). 
Medium-chain triglycerides (Labrafac Lipophile WL 1349), 
used as the oil phase, were kindly provided by Gattefossé Co. 
(Saint Priest, Cedex, France). Caco-2 cells were purchased from 
the American Type Culture Collection (Manassas, VA, USA). 
Dulbecco’s Modified Eagle Medium and Hank’s balanced 
salt solution (HBSS) were purchased from Genom Biotech 
Co., Ltd (Hangzhou, China). Deionized water was prepared 
using a Milli-Q purification system (Millipore, Billerica, 
MA, USA). MTT was from Sigma Chemical Co. (St Louis). 
All other chemicals were of analytical grade and were used 
as received.
Preparation of nanoemulsions
Protein solutions (8% WPI, 8% SPI, and 1% β-lg, w/v) in 
water were prepared as described previously by Chen and International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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Subirade29 and Chen et al.35 Briefly, WPI, SPI, and β-lg 
  solutions were prepared by dispersing the protein powder 
into deionized water with stirring for 1 hour at 25°C. The 
solution was then adjusted to pH 7.0 using 1 M sodium 
hydroxide. To denature the nonpolar and disulfide bonds 
buried in the protein interior and thus increase the emulsify-
ing capacity of the proteins, the SPI, WPI, and β-lg solutions 
were heated to 105°C, 85°C, and 85°C, respectively, in closed 
centrifuge tubes (50 mL, Corning Incorporated, MA, USA) 
for 30 minutes (Figure 1A). The denatured protein solution 
was then cooled to 25°C for 2 hours.
Blank nanoemulsions were prepared using a two-step 
procedure. A coarse emulsion was prepared by homogenizing 
oil phase with aqueous phase using a high-speed Ultra-Turrax 
blender (QilinBeier, Jiangsu, China) operating at 20,000 rpm 
for 0.5 minutes. Afterwards, the emulsions were further 
homogenized using a high-pressure homogenizer (ATS 
Engineering, Inc., Ontario, Canada) (Figure 1A). To compare 
the emulsifying capacities of the proteins and other surfac-
tants, nanoemulsions using EPC, Cremophor EL and RH 40, 
Poloxamar-188, Solutol HS15, or Tween-80 as emulsifiers 
were also prepared, in which the concentration of emulsifier 
was 1.5% w/v, following a similar procedure to that described 
previously. The nanoemulsions containing FB were prepared 
in the same manner by dissolving FB in the oil phase in 
advance.
Particle size and zeta potential 
determination
The mean particle size and the size distribution of the nano-
emulsions were measured by dynamic light scattering 
(DLS) using a NICOMP 380 DLS instrument (Santa Barbara, 
CA, USA). The nanoemulsion was diluted 500-fold in 
  deionized water before measurement.
The surface charge of the nanoemulsions was investigated 
by measuring the electrophoretic mobility at 25°C using a 
NICOMP 380 ZLS. Nanoemulsions were diluted 50-fold in 
water before measurement.
Physical stability of nanoemulsions
The stability of the nanoemulsions was evaluated using the 
centrifugal acceleration method.36 Briefly, 4 mL of nanoemul-
sion was placed in a 5 mL Eppendorf tube and centrifuged 
at 3000 g for 10 minutes in a desktop centrifuge (Anke 
  TGL-16G, Shanghai). A 0.8 mL sample of the subnatant was 
withdrawn from the bottom of the tube into a pipette with a 
slow and steady motion. Then, the samples were vortex 
mixed for 20 seconds, and 0.1 mL of the samples was trans-
ferred to a 50 mL volumetric flask and diluted with deionized 
water to the desired final volume. The absorbance of the 
diluted nanoemulsions was determined spectrophotometri-
cally at a wavelength of 500 nm. The constant of centrifugal 
stability (Ke) was calculated according to the following 
formula:37
 
ke
AA
A
=
-
×
||
%
0
0
100   (1)
where A0 and A are the absorbance of the diluted nanoemul-
sion before and after centrifugation, respectively.
TeM
TEM was used to characterize the morphology of the nano-
emulsions. Nanoemulsions were placed on copper grids and 
negatively stained with 2% (w/v) phosphotungstic acid for 
5 minutes at room temperature. Finally, the grids bearing 
nanoemulsions were observed with a JEM-1230 transmission 
electron microscope (JEOL, Tokyo, Japan).
Protein aqueous
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Heat denaturation
Native protein Denatured protein Drug molecule
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Figure 1 A) scheme of the process for preparing protein-stabilized nanoemulsions 
and  photographs  of  nanoemulsions.  B) Transmission  electron  microphotography 
of food protein-stabilized nanoemulsions: soy protein isolate (sPI), whey protein 
isolate (WPI), and β-lactoglobulin (β-lg). The scale bar for all images represents 100 nm.
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In vitro cytotoxicity of nanoemulsions
The cytotoxicity of the nanoemulsions was tested by measur-
ing the viability of Caco-2 cells in the presence of varying 
concentrations of blank nanoemulsions. The viability of the 
cells was measured using the MTT assay. Caco-2 cells were 
seeded on 96-well plates at a density of 1 × 104 cells per well 
and cultured for 72 hours. Then, the cell culture medium was 
removed from each well, and the cells were rinsed three times 
with HBSS. Nanoemulsions diluted in HBSS were added to 
each well, and the cells were incubated for 4 hours at 37°C. 
Five wells were used to test each sample. Next, 20 µL of 
MTT solution (5 mg/mL) was added to each well and allowed 
to incubate at 37°C for 4 hours. The growth medium and 
excess MTT in each well were removed. Dimethylsulfoxide 
(150 µL) was added to each well to completely dissolve the 
internalized purple formazan crystals. The 490 nm absor-
bance of each well was measured spectrophotometrically. 
The cytotoxicity of the nanoemulsions was expressed as the 
percentage of cell viability, which was calculated from the 
ratio between the number of cells treated with the nanoemul-
sions to that of the control cells (blank). Cells treated with 
sodium dodecyl sulfate solution (0.5 mg/mL) were used to 
define 0% cell viability; cells exposed to HBSS were used 
to define 100% cell viability. Cell viability was calculated 
according to the following equation:
  Cellviability
A
A
test
control
(%) % =× 100   (2)
where Atest and Acontrol were the absorbance of cells treated 
with nanoemulsions and of cells treated with HBSS, 
respectively.
In vitro drug release
The release profiles of FB from protein-stabilized nanoemul-
sions were performed using a dialysis method. Aliquots of 
nanoemulsions (0.4 mL) were instilled into dialysis tubing 
(14,000 MW cut-off). Release testing was carried out in a 
ZRS-8G release tester (Tianjin, China) according to the 
Chinese Pharmacopoeia Method III (the small beaker 
method). The dialysis bags were placed in a beaker contain-
ing 100 mL of release medium and maintained at 37°C with 
a paddle revolution speed of 50 rpm. The release medium 
was either simulated gastric fluid (SGF) (0.1 M hydrogen 
chloride with or without 0.32% [w/v] pepsin) or simulated 
intestinal fluid (SIF) (pH 6.8 phosphate buffer with or without 
1% [w/v] pancreatin), each of which contained 2% Cremo-
phor EL (w/v) to maintain a sink condition. At various time 
intervals, 0.5 mL of the samples was withdrawn, and after 
centrifugation at 10,600 g for 5 minutes the FB concentrations 
in the samples were determined by high-performance liquid 
chromatography (HPLC). Measurements were conducted in 
triplicate.
Pharmacokinetic study
The bioavailability of SPI-, WPI-, and β-lg-stabilized nano-
emulsions containing FB was evaluated in rats and compared 
with the bioavailability of FB dissolved in oil. Sprague 
Dawley rats (adult male, 250–270 g) used in the experiments 
received care in compliance with the Principles of Laboratory 
Animal Care and the Guide for the Care and Use of 
  Laboratory Animals. Experiments followed protocol 
approved by the Fudan University Institutional Animal Care 
and Use Committee.
The rats were fasted but were allowed free access to water 
for 12 hours before the experiments. The formulations were 
orally administered by gavage to rats at an FB dosage equiva-
lent to 30 mg/kg. The formulations of protein-stabilized 
nanoemulsions consisted of 0.5% FB, 1.5% protein, and 6% 
oil solution. FB oil solution (control) was prepared by dis-
solving 75 mg of FB in 15 mL of oil. After gavage, blood 
samples (0.2 mL) were collected from the tail vein into 
heparinized tubes at the following time points: 0.25, 0.5, 
0.75, 1, 2, 4, 6, 8, 12, 24, and 36 hours. The heparinized blood 
samples were immediately centrifuged at 3000 g for 10 minutes 
in a desktop centrifuge (Anke TGL-16G), and the plasma 
was separated and transferred to microcentrifuge tubes. 
The plasma samples were frozen at -18°C until analysis.
Pharmacokinetic parameters were calculated by noncom-
partmental analysis based on statistical moment theory using 
Microsoft Excel 2003. The pharmacokinetic parameters, such 
as maximum plasma concentration (Cmax) and time of maxi-
mum concentration (Tmax), were obtained directly from the 
plasma concentration–time plots. The area under the plasma 
concentration–time curve up to the last time (t) (AUC0–t) was 
calculated using the linear trapezoidal rule.
HPLc assay
As a prodrug, FB is rapidly metabolized to its major active 
metabolite, fenofibric acid. After oral administration and 
absorption, no intact FB can be detected in the plasma.38 
Therefore, pharmacokinetic evaluation of FB is based on the 
quantification of fenofibric acid in plasma.
The sample preparation and HPLC procedures were 
similar to those described in our previous report.32 The 
  Agilent 1100 series HPLC system (Agilent, Santa Clara, CA, 
USA) consisted of a quaternary pump, a degasser, an auto International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
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sampler, a column heater, and a tunable ultraviolet detector. 
Fenofibric acid was separated at 30°C using a C18 column 
(Diamonsil, 5 µm, 4.6 mm × 250 mm, Dikma, China) with 
a refillable C18 precolumn (2.0 mm × 20 mm, Alltech, 
  Lexington, KT, USA) and detected by measuring the 287 nm 
absorbance of the eluate. Indomethacin (100 µg/mL) was 
used as an internal standard. The mobile phase was a mixture 
of methanol/water/phosphoric acid (70:30:0.1, v/v/v) pumped 
at a flow rate of 1 mL/min.
statistical analysis
The results were expressed as mean ± standard deviation. 
One-way analysis of variance was performed to assess the 
statistical significance of differences among samples. Results 
with P , 0.05 were considered statistically significant.
Results and discussion
Preparation and characterization  
of nanoemulsions
WPI and β-lg dissolved rapidly in water yielding homoge-
nous and clear solutions, whereas SPI dissolved partially in 
water yielding a turbid suspension. After heat denaturation, 
WPI and β-lg solutions remained clear, whereas the viscosity 
of the SPI dispersion decreased significantly. The heating 
procedure was intended to improve the emulsifying capacity 
of the proteins by breaking the disulfide bonds buried inside 
the protein.25 The food protein-stabilized nanoemulsions were 
prepared using a combination of mechanical mixing and 
high-pressure homogenization (Figure 1A). The coarse 
  emulsions prior to homogenization were typically a few 
microns in size, yet they exhibited a wide distribution under 
  photomicroscopy. After homogenization, milky white nano-
emulsions were obtained (Figure 1A) and the particle size 
was reduced dramatically. After homogenization at 800 bars 
for 10 cycles, the particle size of the nanoemulsions was 
further reduced to between 200 nm and 250 nm with a log-
normal distribution. No drug precipitation was observed 
during the preparation of protein-stabilized nanoemulsions 
containing FB. Furthermore, an increase of drug in formula-
tions would not result in drug precipitation. TEM photo-
graphs of the food protein-stabilized nanoemulsions revealed 
a spherical morphology with particle diameters ranging from 
150 nm to 250 nm (Figure 1B), closely corresponding to the 
results obtained by DLS.
It is well known that particle size and distribution, as 
well as physical stability, exert significant influence on the 
bioavailability of nanoemulsions. In this study, we investi-
gated the effects of homogenization pressure and number 
of homogenization cycles, protein concentration, oil-to-water 
ratio, and pH on particle size, polydispersity index (PI), 
and physical stability of the nanoemulsions. Furthermore, 
a comparison of the emulsifying capacity of the three 
food proteins with that of several surfactants was also 
performed.
effect of homogenization pressure  
and number of homogenization cycles
Nanoemulsions with good dispersion can be obtained using 
a high-pressure homogenizer. Figure 2(A-1/B-1) shows 
the effect of homogenization pressure and cycles on Ke, 
particle size, and polydispersity. A considerable decrease in 
particle size and PI was achieved with an increase in pressure 
homogenization and/or the number of cycles. Increasing the 
pressure from 100 bars to 800 bars and the number of cycles 
from 1 to 10 led to a significant reduction in particle size and 
PI, with the β-lg-stabilized nanoemulsions having the smallest 
particle size. However, further increasing the homogenization 
pressure to 1000 bars and the number of cycles to 30 did not 
result in significant smaller particle sizes due to the increased 
surface area and interfacial tension caused by the high homog-
enization energy input.39 PI is a measure of dispersion homo-
geneity with values ranging from 0 to 1. PI values lower than 
0.3 suggest a homogeneous dispersion.40 The nanoemulsions 
stabilized by food proteins revealed a relatively small par-
ticle size ranging from about 200 nm to 250 nm and a very 
narrow size distribution (PI , 0.2) when a homogenization 
pressure of 800 bars was applied for 10 cycles.
Figure 2(A-2/B-2) depicts the effect of homogenization 
pressure and number of cycles on the physical stability of 
nanoemulsions. It was observed that the Ke decreased 
  markedly with an increase in pressure and number of cycles 
(1 to 10), indicating an enhanced stability of the nanoemulsions. 
The nanoemulsion stabilized by β-lg was the most stable. 
It has been reported that an increase in homogenization 
pressure and number of cycles can improve surfactant 
adsorption to the surface of emulsion drops, which plays 
an important role in the stabilization of nanoemulsions.41 
  However, increasing the number of homogenization cycles 
beyond 10 would not further improve the stability of 
  nanoemulsions. When the number of homogenization cycles 
increased to more than 10, the stability of nanoemulsion 
stabilized by WPI and SPI decreased. The log-normal 
size distribution in particle size became bimodal distri-
bution with an increased fraction of larger particles 
(data not shown), owing to too much energy input to the 
nanoemulsions.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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effect of protein concentration
It is known that the concentration of stabilizers influences 
the particle size and polydispersity of an emulsion. Increasing 
the concentrations of SPI and β-lg led to decreases in particle 
size (Figure 3A). However, increasing concentrations of WPI 
led to negligible changes in particle size, probably owing to 
the fact that the surfaces of the droplets were saturated with 
WPI at concentrations greater than 1%.42 The particle size 
of β-lg-stabilized nanoemulsions was much smaller than that 
of the nanoemulsions stabilized by WPI or SPI. PI decreased 
significantly with increasing protein concentrations, indicat-
ing an improvement in the particle size distribution of the 
nanoemulsions.
Figure 3B depicts the influence of stabilizer concentration 
on nanoemulsion stability. Ke decreased with increasing 
concentrations of SPI and WPI, indicating an improved 
stability of the nanoemulsions. It was explained that the 
bimodal size distribution in particle size became a narrower 
and log-normal distribution with an increase in concentrations, 
along with a decrease in the number of large particles (data 
not shown). It has also been reported that greater protein 
concentrations result in larger electrostatic repulsive forces 
between colliding droplets.43 It was observed that the Ke of 
β-lg-stabilized nanoemulsions was not affected markedly 
by β-lg concentration, likely due to greater surface charge 
of β-lg relative to SPI and WPI. In fact, the Ke value of 
nanoemulsions prepared using the lowest concentration of 
β-lg (1%) was not greater than the corresponding values for 
WPI and SPI at the highest concentration (8%), highlighting 
the potent stabilizing effect of β-lg. Intrinsically, it could be 
ascribed to the exposure of more hydrophobic domains on 
the surface of β-lg than that of WPI and SPI, which was 
directly correlated with the probability of its adsorption and 
retention at the interface.44
effect of oil-to-water ratio
The effect of the oil-to-water ratio is shown in Figure 4. 
For the protein-stabilized nanoemulsions, increasing the oil 
phase volume fraction from 5% to 50% resulted in an increase 
in particle size from 250 nm to 300 nm and from 250 nm to 
400 nm for WPI- and SPI-stabilized nanoemulsions, 
  respectively; the homogeneous dispersion was also affected 
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Figure 2 A) effect of homogenization pressure on centrifugal stability (Ke), mean particle size, and polydispersity index (PI) of food protein-stabilized nanoemulsions.   
The number of homogenization cycles for the prepared nanoemulsions was 10. A-1) effect of homogenization pressure on mean particle size (column graph) and PI (line graph). 
A-2) effect of homogenization pressure on Ke. B) effect of cycle number on Ke, mean particle size, and PI of food protein-stabilized nanoemulsions. The homogenization pressure 
for the prepared nanoemulsions was 800 bars. B-1) effect of cycle number on mean particle size (column graph) and PI (line graph). B-2) effect of cycle number on Ke.
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by the oil volume because the PI was increased (Figure 4A). 
The preceding observation can be attributed to the increase 
in the interfacial surface caused by increasing the oil volume. 
Interestingly, no influence of the oil phase volume on the par-
ticle size and PI of nanoemulsions stabilized by β-lg was 
observed, underscoring its efficient emulsification and its 
greater drug-carrying capacity.10
The Ke of β-lg- and SPI-stabilized nanoemulsions 
decreased when the oil phase volume fraction was less 
than 25%, whereas the Ke increased when the fraction was 
greater than 25%. The turning point of Ke from WPI-  stabilized 
nanoemulsions was also at the 25% fraction; however, the 
changing trend of Ke was the opposite (Figure 4B); it was 
ascribed to the change of size distribution in particle size. 
It seemed that the stability of β-lg- and SPI-stabilized nano-
emulsions was more sensitive to variation of the oil phase 
volume than was that of WPI-stabilized nanoemulsions, and 
the most stable nanoemulsions were achieved when the frac-
tion of oil reached 25%. This was owing to the narrower and 
log-normal size distribution without large particles at 
25% fraction (data not shown). Compared with the nanoemul-
sions stabilized by WPI and SPI, the stability of β-lg-stabilized 
nanoemulsions was better, which was attributable to the 
exposure of more surface charge and hydrophobic domains.
effect of pH
The electrical barrier or surface charge plays a very important 
role in stabilizing nanoemulsions. Because proteins are 
  zwitterionic, the nanoemulsions stabilized by food proteins 
in this study are differentially charged subject to pH variation. 
The effect of pH on nanoemulsion stabilization by proteins 
is shown in Figure 5.
A negligible influence of pH on the particle size of nano-
emulsions was observed (Figure 5A). When the pH was 
increased from 7 to 10, the PI was less than 0.3, indicating 
a good monodispersivity of the nanoemulsions.
As shown in Figures 5B and 5C, there was a large influence 
of pH on the zeta potential and stability of nanoemulsions. 
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The zeta potential ranged from -33 mV to -43 mV , -39 mV 
to -50 mV , and -52 mV to -73 mV for SPI-, WPI-, and 
β-lg-stabilized nanoemulsions, respectively. The preceding 
results suggest an improvement in the stability of the nano-
emulsions because at larger zeta potentials colloidal nano-
dispersions are more likely to be stable as the charged 
droplets within them more strongly repel one another, thus 
overcoming the natural tendency to aggregate.45,46 Increasing 
the pH led to a reduction in Ke (Figure 5C), demonstrating 
that nanoemulsion stability was improved. The resultant 
stability was consistent with the zeta potential results show-
ing that increased pH contributed to nanoemulsion stability. 
Furthermore, β-lg-stabilized nanoemulsions displayed 
greater stability with higher absolute values of zeta potential. 
This could be explained by the exposure of more hydrophobic 
domains on the surface of β-lg than WPI and SPI.
comparison of proteins and surfactants 
as emulsifiers
Figure 6A shows the effect of different emulsifiers on the 
particle size and PI. The particle size of β-lg-stabilized blank 
nanoemulsions was similar to that of nanoemulsions stabilized 
by traditional surfactant emulsifiers but with lower PI. The 
preceding results suggest that β-lg has the same emulsifica-
tion capacity as traditional surfactant emulsifiers, producing 
a narrower size distribution. The particle sizes of WPI- and 
SPI-stabilized blank nanoemulsions were slightly larger 
(P , 0.05) than those of traditional surfactant-  stabilized 
nanoemulsions; however, the PIs were smaller, suggesting 
a narrower size distribution.
In nanoemulsions containing FB, the particle size and PI 
of WPI- and SPI-stabilized nanoemulsions were decreased. 
This was possibly due to the reduction in surface tension 
caused by FB, which may partition at the oil/water interface 
and thus act as a coemulsifier. The synergistic effect of drugs 
and emulsifiers on the particle size of emulsions was also 
reported by other researchers.47,48
Figure 6B shows the effect of different emulsifiers on the 
zeta potential and stability of nanoemulsions. All the Ke 
values of protein-stabilized nanoemulsions with or without 
FB were lower than those of nanoemulsions stabilized with 
surfactants, though the difference between the nanoemulsions 
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stabilized by EPC and β-lg-stabilized nanoemulsions was 
not significant when the drug was incorporated. It was indi-
cated that a better stabilization was achieved when the three 
proteins were used as emulsifiers. To understand the underly-
ing mechanisms, we measured the zeta potentials of these 
systems. It is known that greater zeta potentials correspond 
to more stable nanoemulsions, with absolute values above 
30 mV being regarded as an indication of stability and 
enhanced uniformity through the generation of repulsive 
forces among particles that prevent aggregation.45,49 The zeta 
potentials of all protein-stabilized nanoemulsions were 
below -30 mV , having absolute values significantly greater 
than nanoemulsions stabilized by traditional emulsifiers 
(P , 0.05). Furthermore, the steric force, which was weak 
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in small molecular surfactant-stabilized nanoemulsions, 
was also beneficial to the improvement in stability. Notably, 
that additional improvement in stability observed for WPI- 
and SPI-stabilized nanoemulsions containing FB was similar 
to that of nanoemulsions stabilized with traditional emulsifiers. 
The preceding observation was likely due to the synergistic 
effect of drug and emulsifier.47,48
In vitro cytotoxicity of nanoemulsions
Figure 7 shows the cytotoxicity of food protein-stabilized 
nanoemulsions to monolayers of Caco-2 cells. At low con-
centrations of emulsifier (0.5 mg/mL), no cytotoxicity of the 
protein-, EPC-, and Poloxamar-188-stabilized nanoemulsions 
was observed after a 4-hour incubation compared with the 
negative control. However, significant cytotoxicity was 
observed for the nanoemulsions stabilized by traditional 
emulsifiers (P , 0.05). When the emulsifier concentration 
was increased to 2 mg/mL, the viability of cells treated with 
EPC and food protein-stabilized nanoemulsion remained 
greater than 95% relative to the negative control, whereas 
the viability of cells treated with surfactant-stabilized nano-
emulsions decreased dramatically compared with controls 
(P , 0.01). At 3 mg/mL of emulsifier, the viability of cells 
exposed to food protein-stabilized nanoemulsions was greater 
than 85%. For other traditional emulsifiers including EPC, 
a 3 mg/mL concentration caused a significant decrease in 
cell viability (P , 0.01). Importantly, the food proteins had 
a better biocompatibility compared with EPC, though it is 
well known that lecithin is not toxic. The results indicated 
good biocompatibility of β-lg-, SPI-, and WPI-stabilized 
nanoemulsions. This was likely due to the protective effect 
of the proteins on the cells, which is in agreement with the 
results of Han et al26 showing that protein (bovine serum 
albumin) nanoparticles have no cytotoxic effect on cells. 
In addition, the increased hydrophilicity of the surfaces also 
reduces cytotoxicity. Notably, no concentration-dependent 
cytotoxicity of β-lg-stabilized nanoemulsions was observed. 
The preceding result is in agreement with that of a previous 
report indicating that protein-based biofilms can increase cell 
viability.50
In vitro drug release
The in vitro release of FB from the nanoemulsions is shown 
in Figure 8. Less than 10% of the drug was released in SGF 
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or SIF without digestive enzymes due to the poor water 
  solubility of the drug. To test the effect of digestive enzymes 
on drug release, we added the digestive enzymes pepsin and 
pancreatin to the SGF and SIF, respectively. The percentage 
drug release in SGF was not increased in the presence of 
pepsin, indicating that the proteins resist pepsin degradation 
in the gastrointestinal tract (Figure 8A). Pepsin is known to 
preferentially cleave peptide bonds between hydrophobic 
aromatic amino acids; however, the hydrophobic amino acids 
that are adsorbed to the surface of the oil droplets are trapped 
inside the protein during the preparation of nanoemulsions.51 
The hydrophobic amino acids are thus hidden, protecting 
them from pepsin degradation. A significant increase in drug 
release was observed on addition of pancreatin to SIF 
 ( Figure 8B), owing to pancreatic degradation of the proteins.27 
A similar report by Chen and Subirade52 also demonstrated 
that pancreatic digestion promoted drug release from 
microparticles based on the proteins they contained. It seems 
that, to some extent, desirable enteric properties of protein-
stabilized nanoemulsions can be achieved, which is useful 
for delivering a hydrophobic and acid-labile drug to the 
intestine.
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Pharmacokinetic studies
Mean plasma fenofibric acid concentration versus time pro-
files following a single oral dose of the four formulations are 
shown in Figure 9. Mean values of the pharmacokinetic 
parameters are summarized in Table 1.
The Tmax/Cmax of fenofibric acid from β-lg-, WPI-, and 
SPI-stabilized nanoemulsions was 5.60 ± 2.19 h/68.61 ± 
16.94 µg/mL, 4.00 ± 2.45 h/78.06 ± 7.07 µg/mL, and 3.40 ± 
2.79 h/109.11 ± 14.36 µg/mL, respectively. In case of the 
oil solution, Cmax was 51.35 ± 15.31 µg/mL and Tmax was 
11.00 ± 2.00 h, both of which differed significantly from the 
values obtained with protein-stabilized nanoemulsion 
  formulations (P , 0.05). The previous observation indicates 
that the drug was absorbed more rapidly when the nanoemul-
sions were administered orally. The AUC values of β-lg-, 
WPI-, and SPI-stabilized nanoemulsions were 1048.31 ± 
266.76, 1047.32 ± 148.09, and 1496.38 ± 188.13 µg ⋅ h/mL, 
which were significantly greater than those of the oil solution 
(755.85 ± 176.37 µg ⋅ h/mL). The absorption of FB from 
nanoemulsions resulted in a significant increase in bioavail-
ability compared with the oil solution. The lower bioavail-
ability of the lipid solution (medium-chain triglyceride) was 
due to the fact that fast digestion of the medium-chain for-
mulation results in significant drug precipitation in the 
gastrointestinal tract.34,53 Additionally, rats lack a gallbladder, 
and bile salts are secreted into the gastrointestinal tract 
  continuously without a pulsatile response to food or lipids.54 
Thus, drug absorption by the lipid solution in fasted rats is 
limited. In contrast, the bioavailability of protein-stabilized 
nanoemulsions was increased significantly compared with 
the control. It has been reported that nanoemulsions present 
drug in a solubilized form, and the small droplet size provides 
a large interfacial surface area for drug absorption.55,56 
  Furthermore, the droplet size of emulsified lipids can be 
decreased by biliary lipid secretion into the gastrointestinal 
tract.54 It should be noted that the bioavailability of SPI-
stabilized nanoemulsions was dramatically greater than that 
of nanoemulsions stabilized by β-lg and WPI. It is likely that 
Table 1 Pharmacokinetic parameters after oral administration of protein-stabilized fenofibrate nanoemulsions and fenofibrate oil solutions
Formulation Tmax (h) Cmax (μg/mL) AUC0-t (μg ⋅ h/mL)
Fenofibrate oil solution (control) 11.00 ± 2.00   51.35 ± 15.31   755.85 ± 176.37
soybean protein isolate-stabilized nanoemulsions   3.40 ± 2.79a 109.11 ± 14.36b 1496.38 ± 188.13a
Whey protein isolate-stabilized nanoemulsions   4.00 ± 2.45a   78.06 ± 7.07b 1047.32 ± 148.09b
β-lactoglobulin-stabilized nanoemulsions   5.60 ± 2.19a   68.61 ± 16.94b 1048.31 ± 266.76b
Notes: astatistically higher than oil solution (P , 0.01). bstatistically higher than oil solution (P , 0.05).
Abbreviations: AUC0-t, area under the plasma concentration–time curve up to the last time; Cmax, maximum plasma concentration; Tmax, time of maximum concentration.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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SPI is more sensitive to digestion by pancreatin, leading to 
a further reduction in the droplet size of emulsified lipids. 
The results clearly demonstrate that the droplets can be 
stabilized by proteins, and the stabilized lipids enable a 
lipophilic drug to be absorbed more rapidly and better com-
pared with oil solution.
Conclusion
Biocompatible nanoemulsions stabilized by food proteins 
can be produced successfully and deliver a poorly water-
soluble drug in vivo. The nanoemulsions enable the lipophilic 
drug to be absorbed more rapidly and better when compared 
with the oil solution. As emulsifiers, the proteins WPI, SPI, 
and β-lg have better emulsifying capacity and biocompatibil-
ity than do traditional emulsifiers. A much better stability 
was observed in protein-stabilized nanoemulsions relative 
to nanoemulsions stabilized with surfactants. The preceding 
observation was likely due to the greater surface potential of 
proteins. Furthermore, β-lg-stabilized nanoemulsions exhib-
ited greater resistance to gravitational separation and better 
biocompatibility compared with nanoemulsions stabilized 
by the other two proteins. The particle size, stability, and 
zeta potential were affected dramatically by protein concen-
tration, pH, homogenization pressure, and number of cycles. 
Therefore, we conclude that by using the proteins as a sur-
factant, the development of biocompatible and biodegradable 
nanoemulsion systems can be achieved, and the proteins are 
viable replacements for traditional surfactants.
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